India’s listed healthcare stocks outside hospitals and drugmakers include diagnostics chains, medical device makers and contract research firms, businesses that tend to trade at premium multiples because of steady, recurring demand. This piece checks five such healthcare stocks on valuation and profitability, with hospitals and pharmaceuticals covered in their own sector pieces.<\/p>\n
Sector Snapshot (28 September 2026)<\/strong><\/p>\n Quick Answer<\/strong><\/p>\n Dr Lal PathLabs stands out among these healthcare stocks, trading below the industry average valuation while posting the strongest return on equity in the group and an almost debt-free balance sheet. The rest are holds: Metropolis Healthcare and Poly Medicure look reasonable but earn more modest returns, Vijaya Diagnostic Centre carries the richest multiple, and Syngene International’s steep fall has not made it cheap.<\/p>\n<\/div>\n Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n\n
\n Stock<\/th>\n LTP (Rs)<\/th>\n 52W High<\/th>\n 52W Low<\/th>\n P\/E vs Industry<\/th>\n ROE<\/th>\n Our View<\/th>\n<\/tr>\n \n Dr Lal PathLabs<\/a><\/td>\n 1,930.20<\/td>\n 2,038.60<\/td>\n 1,272.60<\/td>\n 59.96 \/ 67.71<\/td>\n 20.13%<\/td>\n Buy on Dips<\/td>\n<\/tr>\n \n Metropolis Healthcare<\/a><\/td>\n 569.10<\/td>\n 609.05<\/td>\n 412.25<\/td>\n 59.48 \/ 67.71<\/td>\n 12.56%<\/td>\n Hold<\/td>\n<\/tr>\n \n Poly Medicure<\/a><\/td>\n 1,665.40<\/td>\n 2,094.30<\/td>\n 1,182.00<\/td>\n 55.86 \/ 67.71<\/td>\n 10.37%<\/td>\n Hold<\/td>\n<\/tr>\n \n Vijaya Diagnostic Centre<\/a><\/td>\n 1,506.20<\/td>\n 1,593.60<\/td>\n 848.00<\/td>\n 83.27 \/ 67.71<\/td>\n 18.07%<\/td>\n Hold<\/td>\n<\/tr>\n \n Syngene International<\/a><\/td>\n 376.40<\/td>\n 678.95<\/td>\n 360.40<\/td>\n 69.14 \/ 67.71<\/td>\n 7.76%<\/td>\n Hold<\/td>\n<\/tr>\n<\/table><\/div>\n